ClinicalTrials.gg
Not yet recruitingNCT06665737G-CSF in NHLUpdated Jan 28, 2025

Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients

A Phase 4 interventional study of Early receiving G-CSF group and Late receiving G-CSF group in Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor and Febrile Neutropenia (FN), sponsored by Department of Medical Services Ministry of Public Health of Thailand. Not yet recruiting at 3 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Department of Medical Services Ministry of Public Health of Thailand · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand — 2 open to participants now, 5 under way, 2 of them phase 3. Lymphoma, Non-Hodgkin · Thailand.

Planned enrollment
11th of 13
126 · median 338
Started
2025
the only one that year
Phase 4
Only one
of the 13
Registered
12th of 13
by date
Lead sponsor
1 of 13
Department of Medical Services Ministry of Public Health of Thailand

Among the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand, this one is the 11th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 4, and was the 12th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this clinical trial is to

Primary Objectives:

  1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study
  2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study

Secondary Objectives:

  1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.
  2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).

All patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.

Read the detailed description

This study aims to analyze the impact of the timing of granulocyte colony-stimulating factor (G-CSF) administration on the prevention of febrile neutropenia (FN) in non-Hodgkin's lymphoma patients undergoing standard chemotherapy. G-CSF is a growth factor that stimulates the production of white blood cell in order to fighting infection. When non-Hodgkin's lymphoma patients receive chemotherapy for eradicating cancer cells. They also have collateral damage those white blood cells and other hematopoietic cell lines.

All patients received standard chemotherapy regimens once every four weeks. The study will compare the efficacy of early G-CSF administration, or late administration, after each course of chemotherapy.

The primary endpoint is the incidence of FN in each chemotherapy course. At the end of each chemotherapy course, patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours). All patients will be followed up to monitor for FN events.

Secondary endpoints include the incidence of myelosuppression and quality of life, assessed during outpatient and emergency department visits.

03

Conditions studied

  • Non-Hodgkin's Lymphoma (NHL)
  • Granulocyte Colony Stimulating Factor
  • Febrile Neutropenia (FN)
  • Myelosuppression Adult

Keywords

  • Non-Hodgkin's lymphoma
  • Febrile neutropenia
  • Granulocyte Colony Stimulating Factor
  • Myelosuppression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or old
  • Confirmed lymphoma undergoing standard chemotherapy
  • Signed an approval
  • Has a good understanding of Thai
  • Available for follow-up after chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases
  • to chemotherapy or G-CSF administration
  • Antibiotic use within 1 week prior to enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    Early receiving G-CSF group

    Early receiving G-CSF group Patients in early receiving G-CSF group accept within 72 hours post chemotherapy

    Drug: Early receiving G-CSF group

  • Placebo comparator
    Late receiving G-CSF group

    Last receiving G-CSF group Patients in early receiving G-CSF group accept after 72 hours post chemotherapy

    Drug: Late receiving G-CSF group

Interventions

  • DrugEarly receiving G-CSF group

    Early receiving G-CSF group will be given within 72 hours post chemotherapy

  • DrugLate receiving G-CSF group

    Late receiving G-CSF group will be given after 72 hours post chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of febrile neutropenia

    Incidence of febrile neutropenia in each course

    Time frame: One year

  2. Incidence of leukopenia and neutropenia

    Incidence of leukopenia and neutropenia in each course

    Time frame: One year

Secondary outcomes

  1. Incidence of grade 3 or 4 of myelosuppression

    Incidence of 3 or 4 myelosuppression in each course

    Time frame: One year

  2. Time of visits to outpatient (OPD) and emergency clinics (ER)

    Incidence of visit to OPD or ER in each course

    Time frame: One year

  3. Quality of life (QoL) after chemotherapy

    Quality of life score daily in each course

    Time frame: One year

07

Study locations

3 sites
  • Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University
    Bangkok, 10400, Thailand
  • Rajavithi Hospital
    Bangkok, 10400, Thailand
  • Internal Medicine Unit, Pranongklao Hospital
    Nontaburi, 11000, Thailand
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Feb 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Oct 30, 2024
StartEst.
Feb 1, 2025
Primary completionEst.
Feb 27, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06665737
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
Collaborators
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Internal Medicine Unit, Pranangklao Hospital
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Feb 1, 2025 (estimated)
Primary completion
Feb 27, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 28, 2025

Study contacts

Praviwan Thungthong PT Rajavithi Hospital, M.D.
Contact
pthungthong@gmail.com
+662-206-2900 ext. 10526
Supat Chamnanchanunt SC Department of Clinical Tropical Medicine, Mahidol University, M.D.
Contact
supat.cha@mahidol.ac.th
+662-354-9100 ext. 2060

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion